Primary viral shedding rate (logVCN/mg dust) |
|
|
.5, no vaccine |
|
4.87 (3.79–5.25), 3.37 (2.79–4.05) |
, no vaccine |
|
3.86 (3.30–4.56), 3.28 (2.71–3.95) |
, no vaccine |
|
3.20 (2.64–3.90), 2.89 (2.34–3.59) |
, HVT |
|
3.79 (3.34–4.20), 2.44 (1.93–3.02) |
, HVT |
|
4.48 (4.19–4.92), 4.56 (4.13–4.91) |
, HVT |
|
2.70 (2.16–3.42), 4.15 (3.58–4.82) |
|
Secondary viral shedding rate (VCN/mg dust) |
|
|
, no vaccine |
|
6.99 (6.72–7.21), 6.89 (6.72–7.07) |
, no vaccine |
|
7.34 (7.17–7.51), 7.58 (7.41–7.76) |
, no vaccine |
|
7.69 (7.51–7.85), 7.52 (7.32–7.72) |
, HVT |
|
6.83 (6.61–7.04), 6.35 (6.18–6.52) |
, HVT |
|
7.49 (7.28–7.70), 7.53 (7.31–7.75) |
, HVT |
|
7.50 (7.32–7.67), 7.29 (7.11–7.46) |
|
Primary delay until viral shedding (days) |
|
|
, no vaccine |
|
6 (2–6), 4 (0–6) |
, no vaccine |
|
4 (0–6), 4 (0–6) |
, no vaccine |
|
3 (0–6), 3 (0–6) |
, HVT |
|
5 (0–6), 2 (0–6) |
, HVT |
|
6 (4–6), 6 (2–6) |
, HVT |
|
3 (0–6), 3 (0–6) |
|
Secondary delay until viral shedding (days) |
|
|
, no vaccine |
|
10 (7–14), 9 (6–13) |
, no vaccine |
|
9 (6–13), 9 (6–13) |
, no vaccine |
|
9 (6–13), 9 (5–13) |
, HVT |
|
12 (8–17), 10 (7–13) |
, HVT |
|
11 (8–14), 12 (8–16) |
, HVT |
|
10 (6–13), 9 (6–13) |
|
Weibull scale intercept |
β0
|
4.54 (4.23–4.87) |
Weibull scale coefficient |
|
|
|
β1
|
−0.53 (−1.01–0.06) |
HVT |
β2
|
0.44 (0.24–0.66) |
|
Weibull scale parameter |
|
|
no vaccine |
|
|
HVT |
|
|
|
|
|
Time until death due to MDV |
|
|